Preemptive drug combo may shield new kidneys from FSGS return

NCT ID NCT03763643

Completed Prevention Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether giving the drug rituximab along with a blood-filtering procedure called plasmapheresis right before a kidney transplant could prevent focal segmental glomerulosclerosis (FSGS) from recurring. The trial enrolled 21 children and adults with FSGS who were getting a kidney transplant. The main goal was to see if this approach was feasible, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rituximab
What this could lead to: If it works, this could point toward a way to prevent FSGS from returning after a kidney transplant, helping patients keep their new kidney longer.
What could go wrong: This is a very early pilot study with only 21 participants, so results may not apply to everyone. The treatment also carries risks like infection from immune suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal segmental glomerulosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOCAL SEGMENTAL GLOMERULOSCLEROSIS

Contacts and locations

Locations

Children's Hospital of Colorado

Aurora, Minnesota, 80045, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Cincinnati Children's Hospital

Cincinnati, Ohio, 45229, United States
Duke University

Durham, North Carolina, 27708, United States
Lurie Children's Hospital

Chicago, Illinois, 60611, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Seattle Children's Hospital

Seattle, Washington, 98105, United States
University of Alabama

Tuscaloosa, Alabama, 35487, United States
University of California at Davis

Davis, California, 95616, United States
University of Cincinnati

Cincinnati, Ohio, 45221, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.